Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Clinical Benefit of ToFAcitinib Treatment in Patients With Moderate to Severe Ulcerative Colitis Under Real-life Conditions of Use: TOFAst Study

NCT04424303 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04424303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04424303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Clinical Benefit of ToFAcitinib Treatment in Patients With Moderate to Severe Ulcerative Colitis Under Real-life Conditions of Use: TOFAst Study
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
December 4, 2020
Completion date
December 8, 2025
Enrollment
152 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis